Custom mRNA vaccine cuts risk of melanoma returning by 42%
A personalized mRNA vaccine cut the risk of melanoma coming back or death by 42% in a major trial. The vaccine, called intismeran, is made by Moderna and Merck. Each one is built from the patient's own tumor. It trains the immune system to attack cancer cells left after surgery. The results will be presented on Saturday in Madrid.
Where this came from. 7 outlets reported this. We read them, then wrote the sixty words above.